The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo

Bone Marrow Transplantation

Volumn 30, Issue 3, 2002, Pages 141-147

  Hassan, Z ^a   Hellstrom Lindberg E ^a   Alsadi, S ^a   Edgren, M ^a   Hagglund H ^a   Hassan, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Busulphan; Glutathione; Hematopoietic progenitor cells; Man; Mouse; Stem cell transplantation

Indexed keywords

ACETYLCYSTEINE; BUSULFAN; BUTHIONINE SULFOXIMINE; CD34 ANTIGEN; GLUTATHIONE; MYELOABLATIVE AGENT; ALKYLATING AGENT;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ERYTHROID PRECURSOR CELL; FEMALE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN LOCALIZATION; VEIN OCCLUSION; ANIMAL; BAGG ALBINO MOUSE; CELL DEATH; CYTOLOGY; DRUG EFFECT; PHYSIOLOGY;

ACETYLCYSTEINE; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BONE MARROW CELLS; BUSULFAN; BUTHIONINE SULFOXIMINE; CELL DEATH; COLONY-FORMING UNITS ASSAY; ERYTHROID PROGENITOR CELLS; GLUTATHIONE; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED BALB C;

EID: 0036670854     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703615     Document Type: Article

References (48)

1. Pharmacokinetics of liposomal busulphan in man
2. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
3. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
4. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
5. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
6. Busulfan bioavailability
7. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
8. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
9. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units
10. Mechanisms of toxicity of hepsulfam in human tumor cell lines
11. Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line
12. The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro
13. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: Differential effects of host conditioning with gamma radiation and cytotoxic drugs
14. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs
15. Sequential studies of bone marrow haemopoietic progenitors (CFU-GEM, BFU-E, CFU-E, CFU-GM) following busulfan treatment in Balb/c mice
16. In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients
17. In vitro busulfan sensitivity of granulocyte-macrophage and erythroid progenitor cells in patients with chronic myelogenous leukemia
18. In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase
19. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow
20. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
21. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study
22. Veno-occlusive disease of the liver after hemopoietic cell transplantation
23. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat
24. Glutathione metabolism and its selective modification
25. Utility of acetylcysteine in treating poisonings and adverse drug reactions
26. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation
27. Modulation of glutathione conjugation in vivo: How to decrease glutathione conjugation in vivo or in intact cellular systems in vitro
28. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)
29. Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat
30. Metabolism of 14C-busulfan in isolated perfused rat liver
31. Determination of tetrahydrothiophene formation as a probe of in vitro busulfan metabolism by human glutathione S-transferase A1-1: Use of a highly sensitive gas chromatographic-mass spectrometric method
32. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi
33. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases
34. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes
35. + cells do not express glutathione S-transferases alpha
36. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages
37. Pharmacokinetics and distribution of liposomal busulfan in the rat: A new formulation for intravenous administration
38. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues
39. Protein measurement with the folin phenol reagent
40. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children
41. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia
42. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents
43. Effect of daily administration of cytotoxic drugs on the erythroid and granulocytic repopulating ability of rat bone marrow
44. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity
45. Radioprotective effect of N-acetylcysteine on granulocyte/macrophage colony-forming cells of human bone marrow
46. Failure of N-acetylcysteine to protect against cis-dichlorodiammineplatinum(II)-induced hematopoietic toxicity in mice
47. The effect of N-acetylcysteine on toxicity of cyclophosphamide and doxorubicin on murine hemopoietic progenitors
48. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft